The GW VRU participated in a Phase 2 randomized clinical trial that evaluated the safety and the immunogenicity of two doses of the MVA-BN vaccine for mpox that were one-fifth and one-tenth the standard dose. The team is excited to announce that the clinical findings have been reported and found that the lower doses were safe, well-tolerated, and produced an immune response in comparison to the standard dose.
Results show safety and immunogenicity of fractional doses of the MVA-BN mpox vaccine
Latest News
Dr. David Diemert, the director of the George Washington University Vaccine Research Unit, weighs in on President Donald Trump's executive order pushing for revisions to how children in the US are vaccinated and what that means for the future.
The GW VRU is a site for a clinical trial to examine Pfizer's new C. diff vaccine.
This was a phase 1, double-blind trial to examine the safety and immunogenicity of a replication-competent recombinant vesicular stomatitis virus-vectored vaccine to reduce the risk of infection and severe illness from Lassa Fever.
